CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate i

• click to rate

  Posted by Two Blokes Mon at 11:30 AM - Filed in Stock - 1 view
  
  - 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion ( 7.2, 8.6 and 10 mg/kg Q3W) -